Pricing Log in Create free account

Larimar Therapeutics, Inc. (LRMR) vs Cartesian Therapeutics, Inc. (RNAC)

Larimar Therapeutics, Inc. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Larimar Therapeutics, Inc. and Cartesian Therapeutics, Inc. are of similar size ($206.7M and $199.1M). Across the 9 metrics below, Cartesian Therapeutics, Inc. leads on 8 and Larimar Therapeutics, Inc. on 1.

Valuation

Metric LRMR RNAC Biotechnology median
P/E n/m n/m 8.50
P/S n/m 104.09 9.71
P/B 1.62 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 56.47 9.21
Earnings yield (97.99%) (94.58%) (33.15%)
Free cash flow yield (75.51%) (42.55%) (25.50%)

Profitability

Metric LRMR RNAC Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (138.41%) 236.88% (56.36%)
Return on assets (108.53%) (42.77%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LRMR RNAC Biotechnology median
Revenue growth (TTM) — (94.81%) 6.02%
EPS growth (last fiscal year) (71.97%) (11.80%) 30.26%
Revenue growth, 5-year CAGR — (29.96%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LRMR RNAC Biotechnology median
Debt to equity 0.00 (0.42) 0.00
Current ratio 4.70 7.48 4.72
Net debt to EBITDA 0.79 0.89 0.96

Dividend

Metric LRMR RNAC Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LRMR RNAC Biotechnology median
Market cap 206.73m 199.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack